Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A combination dietary supplement composed of **eicosapentaenoic acid (EPA)**, **astaxanthin**, and **tocotrienol**. EPA is an omega-3 fatty acid known for its cardiovascular, triglyceride-lowering, and anti-inflammatory properties. Astaxanthin is a xanthophyll carotenoid with potent antioxidant and anti-inflammatory effects. Tocotrienol is a member of the vitamin E family that exhibits antioxidant, cholesterol-lowering, neuroprotective, and anti-cancer activities. The combination is designed to provide enhanced anti-inflammatory and antioxidant effects, with research suggesting possible synergistic actions, including reduced production of inflammatory markers (such as nitric oxide and cytokines), and increased cell viability in immune cells compared to single-component treatments. It is primarily marketed as a dietary supplement aimed at supporting cardiovascular, metabolic, and inflammatory health[1][4][5][6]. No pharmaceutical (prescription or OTC drug) formulation containing this exact combination is currently approved.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on eicosapentaenoic acid + astaxanthin + tocotrienol.